scispace - formally typeset
Open AccessJournal ArticleDOI

Progressive 3-Month Increase in LV Myocardial ECV After Anthracycline-Based Chemotherapy.

Giselle C. Meléndez, +5 more
- 01 Jun 2017 - 
- Vol. 10, Iss: 6, pp 708-709
Reads0
Chats0
TLDR
Following myocardial injury, the left ventricular (LV) myocardia can undergo abnormal expansion (due to inflammation and interstitial fibrosis) that can be identified with cardiac magnetic resonance (CMR) assessments of extracellular volume fraction (ECV).
Abstract: 
Following myocardial injury, the left ventricular (LV) myocardial extracellular matrix (ECM) can undergo abnormal expansion (due to inflammation and interstitial fibrosis) that can be identified with cardiac magnetic resonance (CMR) assessments of extracellular volume fraction (ECV) [(1,2)][1].

read more

Citations
More filters
Journal ArticleDOI

Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol

Geeta Gulati, +22 more
- 01 Jun 2016 - 
TL;DR: In patients treated for early breast cancer with adjuvant anthracycline-containing regimens with or without trastuzumab and radiation, concomitant treatment with candesartan provides protection against early decline in global left ventricular function.
Journal ArticleDOI

Anthracycline Therapy Is Associated With Cardiomyocyte Atrophy and Preclinical Manifestations of Heart Disease.

Thiago Ferreira de Souza, +13 more
- 01 Aug 2018 - 
TL;DR: A decrease in LV mass after anthracycline therapy may result from cardiomyocyte atrophy, demonstrating that mechanisms other than interstitial fibrosis and edema can raise ECV.
Journal ArticleDOI

Cardiovascular Magnetic Resonance in the Oncology Patient

Jennifer H. Jordan, +3 more
- 01 Aug 2018 - 
TL;DR: Prior research involving cardiovascular magnetic resonance for assessing cardiovascular disease in patients with or previously having received treatment for cancer is outlined and described.
Journal ArticleDOI

Irisin ameliorates doxorubicin-induced cardiac perivascular fibrosis through inhibiting endothelial-to-mesenchymal transition by regulating ROS accumulation and autophagy disorder in endothelial cells.

Jian-an Pan, +7 more
- 31 Aug 2021 - 
TL;DR: Wang et al. as mentioned in this paper used a low-dose long-term mouse DIC model, and found that the perivascular fibrosis was involved in its myocardial toxicity with the underlying mechanism of endothelial-to-mesenchymal transition (EndMT).
Journal ArticleDOI

Doxorubicin-Induced Myocardial Fibrosis Involves the Neurokinin-1 Receptor and Direct Effects on Cardiac Fibroblasts

Scott P. Levick, +7 more
- 01 Oct 2019 - 
TL;DR: It is demonstrated that cardiac fibrosis induced by Anth-bC can be reduced by NK-1R blockade, and the residual fibrotic response is likely due to direct Dox effects on cardiac fibroblasts to produce collagen.
References
More filters
Journal ArticleDOI

The pathogenesis of cardiac fibrosis

Ping Kong, +2 more
- 01 Feb 2014 - 
TL;DR: Both experimental and clinical evidence suggests that cardiac fibrotic alterations may be reversible, and understanding the mechanisms responsible for initiation, progression, and resolution of cardiac fibrosis is crucial to design anti-fibrotic treatment strategies for patients with heart disease.
Journal ArticleDOI

Extracellular volume fraction mapping in the myocardium, part 1: evaluation of an automated method

Peter Kellman, +4 more
- 10 Sep 2012 - 
TL;DR: Fully automated motion correction and co-registration of breath-holds significantly improve the quality of ECV maps, thus making the generation ofECV-maps feasible for clinical work flow.
Journal ArticleDOI

Diffuse myocardial fibrosis by T1-mapping in children with subclinical anthracycline cardiotoxicity: relationship to exercise capacity, cumulative dose and remodeling

Edythe B Tham, +9 more
- 10 Jun 2013 - 
TL;DR: Myocardial T1 and ECV were found to be early tissue markers of ventricular remodeling that may represent diffuse fibrosis in children with normal ejection fraction post anthracycline therapy, and are related to cumulative dose, exercise capacity and myocardial wall thinning.
Journal ArticleDOI

Myocardial Extracellular Volume by Cardiac Magnetic Resonance Imaging in Patients Treated With Anthracycline-Based Chemotherapy

Tomas G. Neilan, +14 more
- 01 Mar 2013 - 
TL;DR: The myocardial ECV is elevated in patients with previous anthracycline treatment and is associated with the diastolic function and increased atrial volumes.
Related Papers (5)

Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.

Juan Carlos Plana, +26 more
- 01 Sep 2014 - 

Low to Moderate Dose Anthracycline-Based Chemotherapy Is Associated With Early Noninvasive Imaging Evidence of Subclinical Cardiovascular Disease

Brandon C. Drafts, +12 more
- 01 Aug 2013 - 

2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)

José Luis Zamorano, +34 more
- 21 Sep 2016 - 

2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines

José Luis Zamorano, +15 more
- 21 Sep 2016 - 

Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review.

Paaladinesh Thavendiranathan, +5 more
- 01 Jul 2014 -